MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
ENDRA Life Sciences Retained Earnings 2011-2026 | NDRA
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings ENDRA Life Sciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -103 M | -91.9 M | -81.9 M | -68.7 M | -57.3 M | -45.2 M | -27.7 M | -17.9 M | -12.5 M | -9.74 M | -7.46 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -7.46 M | -103 M | -47.6 M |
Quarterly Retained Earnings ENDRA Life Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -107 M | -106 M | -104 M | -103 M | - | -96.9 M | -94.7 M | -91.9 M | -90.5 M | -87.4 M | -84.8 M | -81.9 M | -78.6 M | -75.1 M | -71.5 M | -68.7 M | -65.6 M | -62.9 M | -59.7 M | -57.3 M | -55.1 M | -57.3 M | -57.3 M | -45.2 M | -45.2 M | -45.2 M | -45.2 M | -27.7 M | -27.7 M | -27.7 M | -27.7 M | -17.9 M | -17.9 M | -17.9 M | -17.9 M | -12.5 M | -12.5 M | -12.5 M | -12.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -12.5 M | -107 M | -57.1 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.13 | -2.74 % | $ 4.89 M |  USA |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M |  Israel |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
Castle Biosciences
CSTL
|
-200 M | $ 25.75 | 3.0 % | $ 715 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 195.6 | 0.17 % | $ 21.7 B | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
-499 M | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
2.43 B | $ 65.94 | -1.51 % | $ 25.7 B | USA |
 |
Co-Diagnostics
CODX
|
4.6 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | $ 104.91 | - | $ 19.8 B | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
590 M | $ 16.33 | 5.29 % | $ 494 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 158.0 | 2.86 % | $ 7.83 B | USA |
 |
IQVIA Holdings
IQV
|
7.42 B | $ 166.96 | 0.54 % | $ 28.7 B | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
-720 M | $ 1.46 | 26.96 % | $ 1.86 M | USA |
 |
Interpace Biosciences
IDXG
|
-235 M | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
IDEXX Laboratories
IDXX
|
6.39 B | $ 578.51 | 0.22 % | $ 46.5 B | USA |
 |
Agilent Technologies
A
|
348 M | $ 112.02 | 0.65 % | $ 34.1 B | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 123.79 | -0.43 % | $ 19.7 B | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 100.35 | 0.65 % | $ 8.28 B |  Irlanda |
 |
DarioHealth Corp.
DRIO
|
-452 M | $ 7.5 | -6.13 % | $ 29.9 M | Israel |
 |
Guardant Health
GH
|
-2.99 B | $ 84.9 | -0.33 % | $ 10.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.45 B | - | - | $ 10.6 B |  Niderland |
 |
CareDx, Inc
CDNA
|
-735 M | $ 17.56 | 2.39 % | $ 936 M | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 75.73 | -0.92 % | $ 5.11 B | USA |
 |
Celcuity
CELC
|
-272 M | $ 106.75 | 0.67 % | $ 4.21 B | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 456.93 | 0.98 % | $ 13.2 B | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 264.42 | 0.54 % | $ 22 B | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
9.24 B | $ 1 239.07 | 2.87 % | $ 25.5 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.66 | 1.75 % | $ 432 M | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 8.1 | 1.76 % | $ 1.04 B | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 17.51 | 1.1 % | $ 392 M | USA |
 |
Natera
NTRA
|
-1.94 B | $ 200.09 | 2.46 % | $ 19.7 B | USA |
 |
OPKO Health
OPK
|
-2.07 B | $ 1.15 | 2.68 % | $ 798 M | USA |
 |
Pacific Biosciences of California
PACB
|
-2.7 B | $ 1.39 | 4.51 % | $ 417 M | USA |
 |
RadNet
RDNT
|
-95.4 M | $ 61.74 | 0.41 % | $ 4.64 B | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |